The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy
Abstract
OBJECTIVES: To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results. DESIGN AND SETTING: Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31-month study period ended December 31, 1990. METHODS: Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4+ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status. RESULTS: Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4+ cells (median 0.33 vs 0.56 x 10(9)/L, P less than .01) compared with tuberculin reactors, although neither clinical status nor CD4+ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n = 18) or of unknown (n = 34) HIV serological status developed active tuberculosis during the study period (P less than .05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [Cl], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 100 person-years (95% Cl, 2.6 to 24.7; P = 0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% Cl, 1.3 to 18.0). CONCLUSION: Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574
Self-citationTuberculosis in Patients with Human Immunodeficiency Virus Infection
Havlir, D. V., & Barnes, P. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400507 · Cited by 1,461
Daley, C. L., Small, P. M., Schecter, G. F., Schoolnik, G. K., McAdam, R. A., Jacobs, W. R., & Hopewell, P. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260404 · Cited by 986
Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users
Schoenbaum, E. E., Hartel, D., Selwyn, P. A., Klein, R. S., Davenny, K., Rogers, M., Feiner, C., & Friedland, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909283211306 · Cited by 494
Self-citationTuberculosis as a Manifestation of the Acquired Immunodeficiency Syndrome (AIDS)
Sunderam, G. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380030064029 · Cited by 490
Treatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477
Tuberculosis in the United States
Rieder, H. L. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430030073037 · Cited by 318
Castro, K. G., Hutton, M. D., Mullan, R. J., Polder, J. A., & Snider, D. E. (1990) · PsycEXTRA Dataset · doi:10.1037/e546022006-001 · Cited by 289
Tuberculosis and Human Immunodeficiency Virus Infection
Chaisson, R. E., & Slutkin, G. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.1.96 · Cited by 222
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS
Selwyn, P. A., Feingold, A. R., Hartel, D., Schoenbaum, E. E., Alderman, M. H., Klein, R. S., & Friedland, G. H. (1988) · AIDS · doi:10.1097/00002030-198808000-00005 · Cited by 218
Self-citation
Cited by
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
(2016) · Pediatric Clinical Practice Guidelines & Policies · doi:10.1542/9781610020190-part06-targeted · Cited by 920
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection
Dinnes, J., Deeks, J., Kunst, H., Gibson, A., Cummins, E., Waugh, N., Drobniewski, F., & Lalvani, A. (2007) · Health Technology Assessment · doi:10.3310/hta11030 · Cited by 666
Metadata
- Authors
- Selwyn, P. A.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1992-07-22
- Volume
- 268
- Issue
- 4
- Pages
- 504
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1983886050
- Cited by
- 299
- References
- 15
- FWCI
- 22.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy. https://app.cochat.ai/papers/10.1001/jama.1992.03490040080029
- The paper
- Selwyn, P. A. (1992). High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1992.03490040080029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.